- Home
- GRCE
as 11-27-2024 2:35pm EST
Stocks
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 30.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 29.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.98 - $3.60 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GRACE THERAPEUTICS INC News
GRCE Breaking Stock News: Dive into GRCE Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
9 days ago
GRCE: FY:25 Second Quarter Results
Simply Wall St.
12 days ago
Grace Therapeutics And 2 Other US Penny Stocks To Watch
GlobeNewswire
14 days ago
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
Zacks Small Cap Research
24 days ago
GRCE: Initiating Coverage – From Confusion to Infusion
GlobeNewswire
a month ago
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024
Compare GRCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRCE GRACE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.